$659 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 108 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | New | REGENERON PHARMACEUTICALS | $14,291,000 | – | 41,500 | +100.0% | 2.17% | – |
| QQQ | New | POWERSHARES QQQ TRUSTput | $12,810,000 | – | 80,000 | +100.0% | 1.94% | – |
| INNT | New | INNOVATE BIOPHARMACEUTICLS I | $12,256,000 | – | 980,502 | +100.0% | 1.86% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INCcall | $6,532,000 | – | 200,000 | +100.0% | 0.99% | – |
| ARQL | New | ARQULE INC | $6,521,000 | – | 2,264,136 | +100.0% | 0.99% | – |
| MNOV | New | MEDICINOVA INC | $6,447,000 | – | 630,838 | +100.0% | 0.98% | – |
| KURA | New | KURA ONCOLOGY INC | $6,188,000 | – | 330,000 | +100.0% | 0.94% | – |
| MSFT | New | MICROSOFT CORP | $6,101,000 | – | 66,850 | +100.0% | 0.93% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $5,668,000 | – | 302,275 | +100.0% | 0.86% | – |
| FLEX | New | FLEX LTDord | $5,027,000 | – | 307,839 | +100.0% | 0.76% | – |
| DK | New | DELEK US HLDGS INC NEW | $4,977,000 | – | 122,284 | +100.0% | 0.76% | – |
| RTRX | New | RETROPHIN INC | $4,919,000 | – | 220,000 | +100.0% | 0.75% | – |
| REPH | New | RECRO PHARMA INC | $4,010,000 | – | 364,197 | +100.0% | 0.61% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $3,545,000 | – | 427,086 | +100.0% | 0.54% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $3,377,000 | – | 131,100 | +100.0% | 0.51% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $3,374,000 | – | 160,000 | +100.0% | 0.51% | – |
| ENDP | New | ENDO INTL PLC | $3,267,000 | – | 550,000 | +100.0% | 0.50% | – |
| GEMP | New | GEMPHIRE THERAPEUTICS INC | $3,132,000 | – | 481,046 | +100.0% | 0.48% | – |
| QURE | New | UNIQURE NV | $2,999,000 | – | 127,600 | +100.0% | 0.46% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $2,984,000 | – | 270,000 | +100.0% | 0.45% | – |
| FIXX | New | HOMOLOGY MEDICINES INC | $2,487,000 | – | 133,000 | +100.0% | 0.38% | – |
| PRGO | New | PERRIGO CO PLC | $1,600,000 | – | 19,221 | +100.0% | 0.24% | – |
| GILT | New | GILAT SATELLITE NETWORKS LTD | $985,000 | – | 111,646 | +100.0% | 0.15% | – |
| SEDG | New | SOLAREDGE TECHNOLOGIES INC | $904,000 | – | 17,190 | +100.0% | 0.14% | – |
| RDWR | New | RADWARE LTDord | $389,000 | – | 18,230 | +100.0% | 0.06% | – |
| CSTE | New | CAESARSTONE LTD | $240,000 | – | 12,195 | +100.0% | 0.04% | – |
| SITE | New | SITEONE LANDSCAPE SUPPLY INC | $231,000 | – | 3,000 | +100.0% | 0.04% | – |
| GLIBA | New | GCI LIBERTY INC | $159,000 | – | 3,000 | +100.0% | 0.02% | – |
| LPSN | New | LIVEPERSON INC | $2,000 | – | 136 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.